The novel atypical antipsychotic cariprazine demonstrates dopamine D(2) receptor‐dependent partial agonist actions on rat mesencephalic dopamine neuronal activity

AIM: Cariprazine, a dopamine D(3)‐preferring D(3)/D(2) receptor partial agonist, is FDA approved for the treatment of schizophrenia and acute manic or mixed episodes of bipolar disorder. This study used in vivo electrophysiological techniques in anesthetized rats to determine cariprazine's effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Delcourte, Sarah, Ashby, Charles R., Rovera, Renaud, Kiss, Béla, Adham, Nika, Farkas, Bence, Haddjeri, Nasser
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282959/
https://www.ncbi.nlm.nih.gov/pubmed/29729086
http://dx.doi.org/10.1111/cns.12867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282959/
https://www.ncbi.nlm.nih.gov/pubmed/29729086
http://dx.doi.org/10.1111/cns.12867

Ejemplares similares